Recent Management and Prevention of Bone Complications Supportive Care News

Xgeva Reduces Bone Complications From Prostate Cancer (February 25, 2011)

Among men with bone metastases from prostate cancer, Xgeva™ (denosumab) was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. Results from... Continue Reading

Xgeva Delays Bone Complications in Women with Metastatic Breast Cancer (December 21, 2010)

In a study of women with bone metastases from breast cancer, Xgeva™ (denosumab) delayed bone complications for five months longer than Zometa® (zoledronic acid). These updated results from a Phase III... Continue Reading

Denosumab Delays Bone Complications in Women with Metastatic Breast Cancer (November 23, 2010)

Among women with bone metastases from breast cancer, denosumab may be more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture. The results of this Phase... Continue Reading

Denosumab More Effective Than Zometa at Delaying Bone Complications (October 15, 2010)

Among patients with multiple myeloma or bone metastases from breast cancer, prostate cancer, or other solid tumors, denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing... Continue Reading

Bisphosphonates May Provide Breast Cancer Benefits (December 11, 2009)

Studies presented at the 2009 San Antonio Breast Cancer Symposium suggest that the class of bone drugs known as bisphosphonates may reduce the risk of breast cancer and may help to maintain bone density... Continue Reading

Denosumab Reduces Bone Complications in Breast Cancer Patients with Bone Metastases (December 10, 2009)

Among women with bone metastases from breast cancer, the investigational drug denosumab was more effective than Zometa® (zoledronic acid) at delaying or preventing bone complications such as fracture.... Continue Reading

Denosumab Provides Bone Benefits in Advanced Cancer (September 21, 2009)

Among patients with bone metastases from cancers other than breast or prostate cancer, denosumab is at least as effective as Zometa® (zoledronic acid) at reducing the risk of bone complications. These... Continue Reading

Denosumab Reduces Fractures in Postmenopausal Osteoporosis (August 12, 2009)

Denosumab increases bone mineral density (BMD) and reduces the risk of vertebral fractures in women with postmenopausal osteoporosis, according to the results of a study published in the New England Journal... Continue Reading

Denosumab Reduces Fractures in Non-metastatic Prostate Cancer (August 11, 2009)

Men undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer experienced a 62% reduction in risk of vertebral fractures when treated with denosumab compared to men treated with... Continue Reading

Denosumab Effective in Patients with Bone Metastases (August 7, 2009)

Among patients with bone metastases from cancers other than breast cancer or prostate cancer, the investigational drug denosumab was as effective as Zometa® (zoledronic acid) at reducing the risk of bone... Continue Reading

Next Page »